Company news
Recce Pharmaceuticals Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Safety Committee Approves Expansion of Ph I/II DFI Trial
February 25, 2024
RCE Establishes Strategic Partnership in South-East Asia
February 5, 2024
Positive Ph I/II DFI Efficacy Data to Support Site Expansion
January 17, 2024
Murdoch Children's R327 Efficacy UTI in-vivo
December 27, 2023
RCE Awarded Further $11.17m Advanced Overseas Finding
December 15, 2023
RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
December 14, 2023
Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
December 13, 2023
Canadian Patent Granted for RECCE Anti-Infectives
November 22, 2023
Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
November 6, 2023
Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
October 23, 2023
Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
September 22, 2023
Placement and Entitlement Offer
September 11, 2023
Opening R&D Address at World AMR Congress
September 7, 2023
RECCE Trademark Registered - Vietnam
September 6, 2023
Additional Positive Patient Cases - Special Access Scheme
August 31, 2023
Appendix 4E and Unaudited Preliminary Report
August 31, 2023
Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
August 28, 2023
Patients Dosed in R327 Diabetic Foot Infection Trial
August 22, 2023
Phase I/II Burn Wound Infection Trial Stage 1 Complete
August 21, 2023
Positive Patients Update - Special Access Scheme
August 7, 2023
Australian Patent Granted for RECCE Anti-Infectives
August 3, 2023
Bonus Canadian R&D Rebate Received
July 28, 2023
Scientia Completes Cohort Dosing in Phase I/II UTI Trial
July 28, 2023
Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
July 24, 2023
Clarification - 5x Higher Concentration in Urine & Plasma
July 20, 2023
Phase I Clinical Trial Data Review Complete
July 19, 2023
A$801,604 R&D Rebate Advance Received
July 12, 2023
First Cohort Dosed in Rapid Infusion Phase I/II UTI study
July 10, 2023
Ethics Approval for Phase I/II UTI Trial Expansion
June 29, 2023
Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
April 17, 2023
New Family 4 Patent to be Granted for RECCE Anti-Infectives
April 10, 2023
Recce Receives Further A$973,144 R&D Advance
April 4, 2023
Corporate Presentation - WI Emergence 2023
March 22, 2023
Recce Selects CMAX for Phase I/II UTI Clinical Trial
February 19, 2023
A$6.21m Received from R&D Rebate Payments
January 24, 2023
JP Morgan Healthcare Conference
January 10, 2023
Australian Patent to be Granted for RECCE Anti-Infectives
January 9, 2023
Anti-Infective Research Unit est. at Murdoch Childrens
December 15, 2022
Approval to Start Phase I/II Diabetic Foot Ulcer Study
December 8, 2022
Anti-Infective Portfolio Update and Webinar details
October 18, 2022
Pause in trading
October 17, 2022
R327 COVID Study Update
October 17, 2022
Expansion and Acceleration of Clinical Programs
September 27, 2022
Appendix 4E
August 31, 2022
Phase I Clinical Trial of R327 I.V. - 6000mg Complete
August 21, 2022
Corporate Presentation - Aussie Equities Day 2022
July 28, 2022
Phase I Positive Safety Data - 4000mg Complete
June 21, 2022
Phase I Clinical Trial R327 Advances to 4000mg
May 20, 2022
Corporate Presentation - Biotech Investor Lunch
May 16, 2022
Phase I Clinical Trial R327 Advances to High Dose Cohort
April 12, 2022
Decks
The 5 newest of 45 decks. Every deck is listed under its year.
- Shareholder Meeting (November 2026)
Shareholder meeting · 19 slides · Nov 6, 2026
- Investor Presentation (November 2026)
Investor deck · 45 slides · November 2026
- Investor Presentation (October 2026)
Investor deck · 42 slides · October 2026
- Shareholder Meeting (September 2026)
Shareholder meeting · 10 slides · Sep 2, 2026
- Investor Presentation (September 2026)
Investor deck · 42 slides · September 2026